APO Research
Talk to an analyst

APO RESEARCH · REPORT

Monoclonal Antibody Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Monoclonal Antibody Biologics and Biosimilars Industry Growth and Trends Forecast to 2032

20 December 2025100 pages

Choose your research edition.

Industry ResearchMonoclonal Antibody Biologics and Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Monoclonal Antibody Biologics and Biosimilars Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Monoclonal Antibody Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Monoclonal Antibody Biologics and Biosimilars Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Monoclonal Antibody Biologics and Biosimilars Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

According to APO Research, the global Monoclonal Antibody Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Monoclonal Antibody Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Monoclonal Antibody Biologics and Biosimilars market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Biogen and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Monoclonal Antibody Biologics and Biosimilars market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Monoclonal Antibody Biologics and Biosimilars market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Monoclonal Antibody Biologics and Biosimilars market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Monoclonal Antibody Biologics and Biosimilars.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Monoclonal Antibody Biologics and Biosimilars market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Monoclonal Antibody Biologics and Biosimilars Market by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Biogen

Amgen

AbbVie

Sobi

Innovent Biologics

Celltrion

3SBIO

Monoclonal Antibody Biologics and Biosimilars Segment by Type

Biologics

Biosimilars

Monoclonal Antibody Biologics and Biosimilars Segment by Application

Cancer

Autoimmune Disease

Other

Monoclonal Antibody Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Monoclonal Antibody Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Monoclonal Antibody Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Monoclonal Antibody Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Monoclonal Antibody Biologics and Biosimilars companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Monoclonal Antibody Biologics and Biosimilars Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2021-2026) Table 4. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2027-2032) Table 6. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2026) Table 9. Global Monoclonal Antibody Biologics and Biosimilars Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Monoclonal Antibody Biologics and Biosimilars Market Size Share Forecasted by Type (2027-2032) Table 11. North America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2026) Table 24. Global Monoclonal Antibody Biologics and Biosimilars Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Monoclonal Antibody Biologics and Biosimilars Market Size Share Forecasted by Application (2027-2032) Table 26. North America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Monoclonal Antibody Biologics and Biosimilars Industry Trends Table 37. Monoclonal Antibody Biologics and Biosimilars Industry Drivers Table 38. Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges Table 39. Monoclonal Antibody Biologics and Biosimilars Industry Restraints Table 40. Global Monoclonal Antibody Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Monoclonal Antibody Biologics and Biosimilars Revenue Market Share by Company (2021-2026) Table 42. Global Monoclonal Antibody Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Monoclonal Antibody Biologics and Biosimilars Key Company Headquarters & Area Served Table 44. Global Monoclonal Antibody Biologics and Biosimilars Company, Product Type & Application Table 45. Global Monoclonal Antibody Biologics and Biosimilars Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Monoclonal Antibody Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 52. Sanofi Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Novartis Company Information Table 59. Novartis Business Overview Table 60. Novartis Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 62. Novartis Recent Development Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 67. Merck Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 72. Roche Recent Development Table 73. Eli Lilly Company Information Table 74. Eli Lilly Business Overview Table 75. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 77. Eli Lilly Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 82. Pfizer Recent Development Table 83. Biogen Company Information Table 84. Biogen Business Overview Table 85. Biogen Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 87. Biogen Recent Development Table 88. Amgen Company Information Table 89. Amgen Business Overview Table 90. Amgen Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 92. Amgen Recent Development Table 93. AbbVie Company Information Table 94. AbbVie Business Overview Table 95. AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 97. AbbVie Recent Development Table 98. Sobi Company Information Table 99. Sobi Business Overview Table 100. Sobi Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 102. Sobi Recent Development Table 103. Innovent Biologics Company Information Table 104. Innovent Biologics Business Overview Table 105. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 107. Innovent Biologics Recent Development Table 108. Celltrion Company Information Table 109. Celltrion Business Overview Table 110. Celltrion Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 112. Celltrion Recent Development Table 113. 3SBIO Company Information Table 114. 3SBIO Business Overview Table 115. 3SBIO Monoclonal Antibody Biologics and Biosimilars Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio Table 117. 3SBIO Recent Development Table 118. North America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 120. North America Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2026) Table 121. North America Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. North America Monoclonal Antibody Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 123. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 125. Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2026) Table 126. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Europe Monoclonal Antibody Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 130. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2026) Table 131. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 133. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2026) Table 136. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America Monoclonal Antibody Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 138. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2026) Table 141. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share Forecast by Country (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Monoclonal Antibody Biologics and Biosimilars Product Image Figure 3. Global Monoclonal Antibody Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 5. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region: 2025 VS 2032 Figure 6. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Region (2021-2032) Figure 7. North America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Biologics Image Figure 13. Global Biologics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Biosimilars Image Figure 15. Global Biosimilars Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Monoclonal Antibody Biologics and Biosimilars Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Type 2025 VS 2032 Figure 18. North America Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 19. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 21. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Share by Type (2021-2032) Figure 23. Cancer Image Figure 24. Global Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Autoimmune Disease Image Figure 26. Global Autoimmune Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Other Image Figure 28. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Monoclonal Antibody Biologics and Biosimilars Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Monoclonal Antibody Biologics and Biosimilars Market Share by Application 2025 VS 2032 Figure 31. North America Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 32. Europe Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 34. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Monoclonal Antibody Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Monoclonal Antibody Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 41. Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 44. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 47. Latin America Monoclonal Antibody Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Monoclonal Antibody Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 50. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Cancer
  • Autoimmune Disease
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Biogen
  • Amgen
  • AbbVie
  • Sobi
  • Innovent Biologics
  • Celltrion
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2032)
  5. 1.4.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2021-2026)
  6. 1.4.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Region (2027-2032)
  7. 1.5 Key Regions Monoclonal Antibody Biologics and Biosimilars Market Size (2021-2032)
  8. 1.5.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (2021-2032)
2 Monoclonal Antibody Biologics and Biosimilars Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Biologics
  3. 2.1.2 Biosimilars
  4. 2.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Type
  5. 2.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Monoclonal Antibody Biologics and Biosimilars Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Regions
  9. 2.3.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Type (2021-2026)
3 Monoclonal Antibody Biologics and Biosimilars Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Cancer
  3. 3.1.2 Autoimmune Disease
  4. 3.1.3 Other
  5. 3.2 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Application
  6. 3.2.1 Global Monoclonal Antibody Biologics and Biosimilars Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Monoclonal Antibody Biologics and Biosimilars Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Monoclonal Antibody Biologics and Biosimilars Market Size by Regions
  10. 3.3.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Monoclonal Antibody Biologics and Biosimilars Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Monoclonal Antibody Biologics and Biosimilars Industry Trends
  2. 4.2 Monoclonal Antibody Biologics and Biosimilars Industry Drivers
  3. 4.3 Monoclonal Antibody Biologics and Biosimilars Industry Opportunities and Challenges
  4. 4.4 Monoclonal Antibody Biologics and Biosimilars Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Monoclonal Antibody Biologics and Biosimilars Revenue (2021-2026)
  2. 5.2 Global Monoclonal Antibody Biologics and Biosimilars Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Monoclonal Antibody Biologics and Biosimilars Key Company Headquarters & Area Served
  4. 5.4 Global Monoclonal Antibody Biologics and Biosimilars Company, Product Type & Application
  5. 5.5 Global Monoclonal Antibody Biologics and Biosimilars Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Monoclonal Antibody Biologics and Biosimilars Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Monoclonal Antibody Biologics and Biosimilars Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Monoclonal Antibody Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Merck Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Roche Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Biogen
  44. 6.8.1 Biogen Company Information
  45. 6.8.2 Biogen Business Overview
  46. 6.8.3 Biogen Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Biogen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  48. 6.8.5 Biogen Recent Developments
  49. 6.9 Amgen
  50. 6.9.1 Amgen Company Information
  51. 6.9.2 Amgen Business Overview
  52. 6.9.3 Amgen Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Amgen Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  54. 6.9.5 Amgen Recent Developments
  55. 6.10 AbbVie
  56. 6.10.1 AbbVie Company Information
  57. 6.10.2 AbbVie Business Overview
  58. 6.10.3 AbbVie Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 AbbVie Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  60. 6.10.5 AbbVie Recent Developments
  61. 6.11 Sobi
  62. 6.11.1 Sobi Company Information
  63. 6.11.2 Sobi Business Overview
  64. 6.11.3 Sobi Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Sobi Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  66. 6.11.5 Sobi Recent Developments
  67. 6.12 Innovent Biologics
  68. 6.12.1 Innovent Biologics Company Information
  69. 6.12.2 Innovent Biologics Business Overview
  70. 6.12.3 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Innovent Biologics Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  72. 6.12.5 Innovent Biologics Recent Developments
  73. 6.13 Celltrion
  74. 6.13.1 Celltrion Company Information
  75. 6.13.2 Celltrion Business Overview
  76. 6.13.3 Celltrion Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Celltrion Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  78. 6.13.5 Celltrion Recent Developments
  79. 6.14 3SBIO
  80. 6.14.1 3SBIO Company Information
  81. 6.14.2 3SBIO Business Overview
  82. 6.14.3 3SBIO Monoclonal Antibody Biologics and Biosimilars Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 3SBIO Monoclonal Antibody Biologics and Biosimilars Product Portfolio
  84. 6.14.5 3SBIO Recent Developments
7 North America
  1. 7.1 North America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 7.3 North America Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 8.3 Europe Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 10.3 South America Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Monoclonal Antibody Biologics and Biosimilars Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst